{"name":"Azienda Ospedaliera Universitaria Integrata Verona","slug":"azienda-ospedaliera-universitaria-integrata-verona","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Libramed","genericName":"Libramed","slug":"libramed","indication":"Other","status":"phase_1"},{"name":"Vistabex","genericName":"Vistabex","slug":"vistabex","indication":"Other","status":"phase_2"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Tixagevimab Cilgavimab","genericName":"Tixagevimab Cilgavimab","slug":"tixagevimab-cilgavimab","indication":"Prevention of COVID-19 in individuals 12 years of age and older","status":"phase_3"}]}],"pipeline":[{"name":"Libramed","genericName":"Libramed","slug":"libramed","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Tixagevimab Cilgavimab","genericName":"Tixagevimab Cilgavimab","slug":"tixagevimab-cilgavimab","phase":"phase_3","mechanism":"Tixagevimab and cilgavimab are monoclonal antibodies that bind to the SARS-CoV-2 spike protein, preventing viral entry into host cells.","indications":["Prevention of COVID-19 in individuals 12 years of age and older"],"catalyst":""},{"name":"Vistabex","genericName":"Vistabex","slug":"vistabex","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiakFVX3lxTE9IeGlpSEhjT0ZHQk1NdWEzVVpLOHVxeXNrSHY4WXlDUWc2RndibHhybWhGSVhBTmxUclpFU0hRY1hQMC1IYzRkVmxNNjVZUFRGb2EyYmNYNGc2RTl2SThoVGwybmc3cC1OdVE?oc=5","date":"2024-08-13","type":"pipeline","source":"Neurology® Journals","summary":"Clinical Reasoning: Hyperventilation-Induced Alternating Hemiplegia With Concomitant Hemispheric EEG Slowing in a 7-Year-Old Girl With Headache - Neurology® Journals","headline":"Clinical Reasoning: Hyperventilation-Induced Alternating Hemiplegia With Concomitant Hemispheric EEG Slowing in a 7-Year","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE51WUc2aEQyRzItOTVRN2tERFZ1S05aZ0pZcTI3OXFPZklxUzRobTBUeldWQkJ5dmxkQjRGWURDNmxDT3BrNFZaSmFNN2hUZWV0dlNPRzZndmRISm1ySDQ5SlEtYVBudmxtcG9oUFRn?oc=5","date":"2019-05-08","type":"pipeline","source":"Recenti Progressi in Medicina","summary":"I farmaci per le malattie rare: la fortuna di essere orfani - Recenti Progressi in Medicina","headline":"I farmaci per le malattie rare: la fortuna di essere orfani","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"phase_1":1,"phase_3":1,"phase_2":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}